
StrideBio, Inc. is a gene therapy company in Research Triangle Park, NC, developing next-generation adeno-associated viral (AAV) vectors for the treatment of rare diseases including NPC1. Our capsid engineering platform uses structural biology to design and select novel AAV capsids with optimal properties including evasion of pre-existing neutralizing antibodies and improved tissue specific tropism. In collaboration with leading clinical researchers in the field, the StrideBio NPC program is making continued progress towards developing a gene therapy approach that is safe and effective for NPC patients.

www.stridebio.com